Expression of MUM1, BCL-6, CD138/syn-1, and CD10 andBCL-6 gene mutations in systemic AIDS-related non-Hodgkin lymphomas
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | ||||
|---|---|---|---|---|---|---|---|---|
| MUM1* . | BCL-6* . | Syn-1* . | CD10* . | EBER . | LMP1* . | |||
| 1 | BL | − | > 75 | − | > 75 | + | − | − |
| 2 | BL | − | 50-75 | − | > 75 | − | + | − |
| 3 | BL | − | < 10 | − | > 75 | nd | − | − |
| 4 | BL | − | < 10 | − | > 75 | nd | + | − |
| 5 | BL | − | > 75 | − | > 75 | nd | + | − |
| 6 | BL | − | 10-25 | − | > 75 | + | + | − |
| 7 | BL | − | 10-25 | − | > 75 | + | − | − |
| 8 | BL | − | > 75 | − | > 75 | + | + | − |
| 9 | BL | − | > 75 | − | > 75 | − | + | − |
| 10 | BL | − | > 75 | − | − | + | − | − |
| 11 | BL | − | > 75 | − | > 75 | − | − | − |
| 12 | BL | − | 50-75 | − | > 75 | + | − | − |
| 13 | BL | − | > 75 | − | > 75 | − | + | − |
| 14 | BL | − | > 75 | − | > 75 | + | − | − |
| 15 | BL | − | > 75 | − | > 75 | + | − | − |
| 16 | BL | − | > 75 | − | > 75 | + | + | − |
| 17 | BL | − | 50-75 | − | > 75 | nd | + | − |
| 18 | BL | +occ. | > 75 | − | > 75 | nd | + | − |
| 19 | BL | +occ. | 25-50 | − | nd | nd | − | − |
| 20 | DLCL | − | − | − | − | nd | − | − |
| 21 | DLCL | − | > 75 | − | > 75 | nd | + | − |
| 22 | DLCL | − | > 75 | − | − | nd | − | − |
| 23 | DLCL | − | 10-25 | − | − | + | − | − |
| 24 | DLCL | − | 50-75 | − | − | + | − | − |
| 25 | DLCL | − | > 75 | − | − | + | − | − |
| 26 | DLCL | − | > 75 | − | > 75 | nd | − | − |
| 27 | DLCL | − | 25-50 | − | − | nd | − | − |
| 28 | DLCL | − | 10-25 | − | − | nd | − | − |
| 29 | DLCL | > 75 | < 10 | − | − | nd | − | − |
| 30 | DLCL | 50-75 | 10-25 | − | − | nd | − | − |
| 31 | DLCL | − | 10-25 | − | − | + | + | − |
| 32 | DLCL | − | 50-75 | − | − | − | − | − |
| 33 | DLCL | − | 50-75 | − | > 75 | nd | − | − |
| 34 | DLCL | − | > 75 | − | − | nd | − | nd |
| 35 | DLCL | > 75 | − | − | nd | nd | + | < 10 |
| 36 | IBL | > 75 | − | > 75 | − | nd | − | − |
| 37 | IBL | < 10 | − | < 10 | − | + | + | < 10 |
| 38 | IBL | > 75 | − | 50-75 | − | − | + | 10-25 |
| 39 | IBL | 50-75 | − | − | − | nd | − | − |
| 40 | IBL | > 75 | − | < 10 | − | nd | + | +occ |
| 41 | IBL | 50-75 | − | < 10 | − | nd | + | 25-50 |
| 42 | IBL | > 75 | − | − | − | nd | + | − |
| 43 | IBL | 50-75 | − | < 10 | − | nd | + | 25-50 |
| 44 | IBL | 50-75 | − | − | − | nd | + | 10-25 |
| 45 | IBL | 25-50 | − | − | − | nd | + | − |
| 46 | IBL | 25-50 | − | 25-50 | > 75 | nd | + | − |
| 47 | IBL | 10-25 | − | − | − | nd | + | − |
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | ||||
|---|---|---|---|---|---|---|---|---|
| MUM1* . | BCL-6* . | Syn-1* . | CD10* . | EBER . | LMP1* . | |||
| 1 | BL | − | > 75 | − | > 75 | + | − | − |
| 2 | BL | − | 50-75 | − | > 75 | − | + | − |
| 3 | BL | − | < 10 | − | > 75 | nd | − | − |
| 4 | BL | − | < 10 | − | > 75 | nd | + | − |
| 5 | BL | − | > 75 | − | > 75 | nd | + | − |
| 6 | BL | − | 10-25 | − | > 75 | + | + | − |
| 7 | BL | − | 10-25 | − | > 75 | + | − | − |
| 8 | BL | − | > 75 | − | > 75 | + | + | − |
| 9 | BL | − | > 75 | − | > 75 | − | + | − |
| 10 | BL | − | > 75 | − | − | + | − | − |
| 11 | BL | − | > 75 | − | > 75 | − | − | − |
| 12 | BL | − | 50-75 | − | > 75 | + | − | − |
| 13 | BL | − | > 75 | − | > 75 | − | + | − |
| 14 | BL | − | > 75 | − | > 75 | + | − | − |
| 15 | BL | − | > 75 | − | > 75 | + | − | − |
| 16 | BL | − | > 75 | − | > 75 | + | + | − |
| 17 | BL | − | 50-75 | − | > 75 | nd | + | − |
| 18 | BL | +occ. | > 75 | − | > 75 | nd | + | − |
| 19 | BL | +occ. | 25-50 | − | nd | nd | − | − |
| 20 | DLCL | − | − | − | − | nd | − | − |
| 21 | DLCL | − | > 75 | − | > 75 | nd | + | − |
| 22 | DLCL | − | > 75 | − | − | nd | − | − |
| 23 | DLCL | − | 10-25 | − | − | + | − | − |
| 24 | DLCL | − | 50-75 | − | − | + | − | − |
| 25 | DLCL | − | > 75 | − | − | + | − | − |
| 26 | DLCL | − | > 75 | − | > 75 | nd | − | − |
| 27 | DLCL | − | 25-50 | − | − | nd | − | − |
| 28 | DLCL | − | 10-25 | − | − | nd | − | − |
| 29 | DLCL | > 75 | < 10 | − | − | nd | − | − |
| 30 | DLCL | 50-75 | 10-25 | − | − | nd | − | − |
| 31 | DLCL | − | 10-25 | − | − | + | + | − |
| 32 | DLCL | − | 50-75 | − | − | − | − | − |
| 33 | DLCL | − | 50-75 | − | > 75 | nd | − | − |
| 34 | DLCL | − | > 75 | − | − | nd | − | nd |
| 35 | DLCL | > 75 | − | − | nd | nd | + | < 10 |
| 36 | IBL | > 75 | − | > 75 | − | nd | − | − |
| 37 | IBL | < 10 | − | < 10 | − | + | + | < 10 |
| 38 | IBL | > 75 | − | 50-75 | − | − | + | 10-25 |
| 39 | IBL | 50-75 | − | − | − | nd | − | − |
| 40 | IBL | > 75 | − | < 10 | − | nd | + | +occ |
| 41 | IBL | 50-75 | − | < 10 | − | nd | + | 25-50 |
| 42 | IBL | > 75 | − | − | − | nd | + | − |
| 43 | IBL | 50-75 | − | < 10 | − | nd | + | 25-50 |
| 44 | IBL | 50-75 | − | − | − | nd | + | 10-25 |
| 45 | IBL | 25-50 | − | − | − | nd | + | − |
| 46 | IBL | 25-50 | − | 25-50 | > 75 | nd | + | − |
| 47 | IBL | 10-25 | − | − | − | nd | + | − |
EBV indicates Epstein-Barr virus; mut, mutation; LMP1, latent membrane protein 1; BL, Burkitt lymphoma; −, negative; +, positive; nd, not done; occ, occasional positive cells; DLCL, diffuse large cell lymphoma; IBL, immunoblastic lymphoma.
Percentages of MUM1, BCL-6, syn-1, CD10, and LMP1+neoplastic cells were assigned to one of the following categories: 0%, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.